Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07291414 · ClinicalTrials.gov registry record · NA

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

A NA study of Malignant Solid Neoplasm and Breast Carcinoma, sponsored by University of Michigan Rogel Cancer Center.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT07291414: Recruiting NA study of Malignant Solid Neoplasm and Breast Carcinoma, sponsored by University of Michigan Rogel Cancer Center.

NCT07291414 is a NA study of Malignant Solid Neoplasm and Breast Carcinoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 80 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07291414, a NA study of Malignant Solid Neoplasm and Breast Carcinoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Primary Outcome

Self-reported system usability will be assessed using the 10-item System Usability Scale. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.

Interventions

  • OTHER Educational Intervention
  • OTHER Electronic Health Record Review
  • OTHER Interview
  • PROCEDURE Follow-Up
  • OTHER Internet-Based Intervention

Study Locations (1)

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2026-01-09
Est. Completion 2028-01-01
Phase NA

What NCT07291414 shows while recruiting

NCT07291414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (93% lower).

The record links to 5 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Educational Intervention is the first listed.

NCT07291414 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT07291414 about?

NCT07291414 is a clinical study titled "A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients". This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, p...

What is the current status of trial NCT07291414?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2026-01-09. Estimated completion is 2028-01-01.

What conditions does trial NCT07291414 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Breast Carcinoma, Prostate Carcinoma, Colorectal Carcinoma, Lung Carcinoma.

What interventions are being tested in trial NCT07291414?

The interventions under investigation include: Educational Intervention (OTHER), Electronic Health Record Review (OTHER), Interview (OTHER), Follow-Up (PROCEDURE), Internet-Based Intervention (OTHER).

Who is sponsoring clinical trial NCT07291414?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07291414 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07291414's enrollment target sits among peer trials

80 100th of 176 higher than 77 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07291414, the US trial registry maintained by the National Library of Medicine. NCT07291414 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.